BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 23482805)

  • 1. Inactivation of 9q22.3 tumor suppressor genes predict outcome for patients with head and neck squamous cell carcinoma.
    Ghosh A; Maiti GP; Bandopadhyay MN; Chakraborty J; Biswas J; Roychoudhury S; Panda CK
    Anticancer Res; 2013 Mar; 33(3):1215-20. PubMed ID: 23482805
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of FANCC and PTCH1 with the development of early dysplastic lesions of the head and neck.
    Ghosh A; Ghosh S; Maiti GP; Mukherjee S; Mukherjee N; Chakraborty J; Roy A; Roychoudhury S; Panda CK
    Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S528-38. PubMed ID: 21861228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alterations in candidate genes PHF2, FANCC, PTCH1 and XPA at chromosomal 9q22.3 region: pathological significance in early- and late-onset breast carcinoma.
    Sinha S; Singh RK; Alam N; Roy A; Roychoudhury S; Panda CK
    Mol Cancer; 2008 Nov; 7():84. PubMed ID: 18990233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive genomic profiling of head and neck squamous cell carcinoma reveals FGFR1 amplifications and tumour genomic alterations burden as prognostic biomarkers of survival.
    Dubot C; Bernard V; Sablin MP; Vacher S; Chemlali W; Schnitzler A; Pierron G; Ait Rais K; Bessoltane N; Jeannot E; Klijanienko J; Mariani O; Jouffroy T; Calugaru V; Hoffmann C; Lesnik M; Badois N; Berger F; Le Tourneau C; Kamal M; Bieche I
    Eur J Cancer; 2018 Mar; 91():47-55. PubMed ID: 29331751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PITX2 and PANCR DNA methylation predicts overall survival in patients with head and neck squamous cell carcinoma.
    Sailer V; Holmes EE; Gevensleben H; Goltz D; Dröge F; de Vos L; Franzen A; Schröck F; Bootz F; Kristiansen G; Schröck A; Dietrich D
    Oncotarget; 2016 Nov; 7(46):75827-75838. PubMed ID: 27716615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NDN and CD1A are novel prognostic methylation markers in patients with head and neck squamous carcinomas.
    Virani S; Bellile E; Bradford CR; Carey TE; Chepeha DB; Colacino JA; Helman JI; McHugh JB; Peterson LA; Sartor MA; Taylor JM; Walline HM; Wolf GT; Rozek LS
    BMC Cancer; 2015 Oct; 15():825. PubMed ID: 26518708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genomic amplification of Fanconi anemia complementation group A (FancA) in head and neck squamous cell carcinoma (HNSCC): Cellular mechanisms of radioresistance and clinical relevance.
    Hess J; Unger K; Orth M; Schötz U; Schüttrumpf L; Zangen V; Gimenez-Aznar I; Michna A; Schneider L; Stamp R; Selmansberger M; Braselmann H; Hieber L; Drexler GA; Kuger S; Klein D; Jendrossek V; Friedl AA; Belka C; Zitzelsberger H; Lauber K
    Cancer Lett; 2017 Feb; 386():87-99. PubMed ID: 27867017
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deletion mapping of chromosome 13q in head and neck squamous cell carcinoma in Indian patients: correlation with prognosis of the tumour.
    Sabbir MG; Roy A; Mandal S; Dam A; Roychoudhury S; Panda CK
    Int J Exp Pathol; 2006 Apr; 87(2):151-61. PubMed ID: 16623759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the methylation profile of exfoliated cell samples from patients with head and neck squamous cell carcinoma.
    Longo AL; Rettori MM; de Carvalho AC; Kowalski LP; Carvalho AL; Vettore AL
    Head Neck; 2014 May; 36(5):631-7. PubMed ID: 23595968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiple tumor types including leiomyoma and Wilms tumor in a patient with Gorlin syndrome due to 9q22.3 microdeletion encompassing the PTCH1 and FANC-C loci.
    Garavelli L; Piemontese MR; Cavazza A; Rosato S; Wischmeijer A; Gelmini C; Albertini E; Albertini G; Forzano F; Franchi F; Carella M; Zelante L; Superti-Furga A
    Am J Med Genet A; 2013 Nov; 161A(11):2894-901. PubMed ID: 24124115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pediatric laryngeal carcinoma in a heterozygous carrier of Fanconi anemia.
    D'Souza AM; Mark J; Demarcantonio M; Leino D; Sisson R; Geller JI
    Pediatr Blood Cancer; 2017 Aug; 64(8):. PubMed ID: 28139070
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetic inactivation of galanin and GALR1/2 is associated with early recurrence in head and neck cancer.
    Misawa K; Misawa Y; Kanazawa T; Mochizuki D; Imai A; Endo S; Carey TE; Mineta H
    Clin Exp Metastasis; 2016 Feb; 33(2):187-95. PubMed ID: 26572146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SMYD2 overexpression is associated with tumor cell proliferation and a worse outcome in human papillomavirus-unrelated nonmultiple head and neck carcinomas.
    Ohtomo-Oda R; Komatsu S; Mori T; Sekine S; Hirajima S; Yoshimoto S; Kanai Y; Otsuji E; Ikeda E; Tsuda H
    Hum Pathol; 2016 Mar; 49():145-55. PubMed ID: 26826421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low blood levels of sTWEAK are related to locoregional failure in head and neck cancer.
    Avilés-Jurado FX; Terra X; Gómez D; Flores JC; Raventós A; Maymó-Masip E; León X; Serrano-Gonzalvo V; Vendrell J; Figuerola E; Chacón MR
    Eur Arch Otorhinolaryngol; 2015 Jul; 272(7):1733-41. PubMed ID: 24858806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor suppressor activity and inactivation of galanin receptor type 2 by aberrant promoter methylation in head and neck cancer.
    Misawa Y; Misawa K; Kanazawa T; Uehara T; Endo S; Mochizuki D; Yamatodani T; Carey TE; Mineta H
    Cancer; 2014 Jan; 120(2):205-13. PubMed ID: 24122450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial.
    Fakhry C; Westra WH; Li S; Cmelak A; Ridge JA; Pinto H; Forastiere A; Gillison ML
    J Natl Cancer Inst; 2008 Feb; 100(4):261-9. PubMed ID: 18270337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alterations of 3p21.31 tumor suppressor genes in head and neck squamous cell carcinoma: Correlation with progression and prognosis.
    Ghosh S; Ghosh A; Maiti GP; Alam N; Roy A; Roy B; Roychoudhury S; Panda CK
    Int J Cancer; 2008 Dec; 123(11):2594-604. PubMed ID: 18792900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aberrant methylation inactivates somatostatin and somatostatin receptor type 1 in head and neck squamous cell carcinoma.
    Misawa K; Misawa Y; Kondo H; Mochizuki D; Imai A; Fukushima H; Uehara T; Kanazawa T; Mineta H
    PLoS One; 2015; 10(3):e0118588. PubMed ID: 25734919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inferior outcomes in immunosuppressed patients with high-risk cutaneous squamous cell carcinoma of the head and neck treated with surgery and radiation therapy.
    Manyam BV; Gastman B; Zhang AY; Reddy CA; Burkey BB; Scharpf J; Alam DS; Fritz MA; Vidimos AT; Koyfman SA
    J Am Acad Dermatol; 2015 Aug; 73(2):221-7. PubMed ID: 26028524
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PDCD1 (PD-1) promoter methylation predicts outcome in head and neck squamous cell carcinoma patients.
    Goltz D; Gevensleben H; Dietrich J; Schroeck F; de Vos L; Droege F; Kristiansen G; Schroeck A; Landsberg J; Bootz F; Dietrich D
    Oncotarget; 2017 Jun; 8(25):41011-41020. PubMed ID: 28487502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.